Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases

BACKGROUND: Visceral metastases account for 48–67% of metastatic breast cancer (MBC) patients and presage a worse overall survival. Previous study suggested potential effect of nab-paclitaxel on patients with visceral metastases subgroups. This phase II trial was conducted to explore the efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yizhao, Gong, Chengcheng, Zhang, Jian, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Li, Ting, Zhao, Yannan, Li, Yi, Hu, Shihui, Wang, Biyun, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565069/
https://www.ncbi.nlm.nih.gov/pubmed/34727875
http://dx.doi.org/10.1186/s12885-021-08921-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565069/
https://www.ncbi.nlm.nih.gov/pubmed/34727875
http://dx.doi.org/10.1186/s12885-021-08921-2

Ejemplares similares